(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 April 2009 (30.04.2009)

PCT

(10) International Publication Number
WO 2009/053038 A3

(51) International Patent Classification:
A61P 35/00 (2006.01) *A61K 31/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2008/008919

(22) International Filing Date: 22 October 2008 (22.10.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07020820.2 24 October 2007 (24.10.2007) EP

(71) Applicants *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). **GLYCART BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 18, CH-8952 Schlieren-Zuerich (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **FERTIG, Georg** [DE/DE]; Wolfbauerweg 6, 82377 Penzberg (DE). **FRIESS, Thomas** [DE/DE]; St. Martin-Strasse 8a, 86911 Diesen-Dettenhofen (DE). **KLEIN, Christian** [DE/DE]; Moraenenweg 5, 82393 Iffeldorf (DE). **UMANA, Pablo** [CH/CH]; Milchbuckstrasse 3, CH-8057 Zuerich (CH).

(74) Agent: **BURGER, Alexander**; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A PROTEASOME INHIBITOR

(57) Abstract: The present invention is directed to the use an type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with a proteasome inhibitor.

Fig. 1



WO 2009/053038 A3

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
25 June 2009